2023
Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance.
Krykbaeva I, Bridges K, Damsky W, Pizzurro G, Alexander A, McGeary M, Park K, Muthusamy V, Eyles J, Luheshi N, Turner N, Weiss S, Olino K, Kaech S, Kluger H, Miller-Jensen K, Bosenberg M. Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance. Cancer Immunology Research 2023, 11: 1332-1350. PMID: 37478171, DOI: 10.1158/2326-6066.cir-22-0699.Peer-Reviewed Original ResearchConceptsPD-1 resistanceDendritic cellsTumor regressionAnti-PD-1 resistanceActivates Dendritic CellsCytokine secretion profilingSystemic cytokine profileTriple therapy combinationInnate immune activationAdaptive immune responsesComplete tumor regressionMajority of miceSignificant clinical challengeMouse melanoma modelT cell activationAgonistic CD40Checkpoint inhibitorsDC subsetsTriple therapyCytokine profileImmune activationCombinatorial immunotherapyTherapy combinationsT cellsClinical challenge
2014
Update on Vaccines for High-Risk Melanoma
Weiss SA, Chandra S, Pavlick AC. Update on Vaccines for High-Risk Melanoma. Current Treatment Options In Oncology 2014, 15: 269-280. PMID: 24788575, DOI: 10.1007/s11864-014-0283-7.Peer-Reviewed Original ResearchConceptsHigh-risk melanomaRole of vaccinesClinical trialsCytotoxic T-lymphocyte antigen-4Death-1 monoclonal antibodyT-lymphocyte antigen-4Cell death-1 monoclonal antibodyImmunogenic solid tumorsOpinion statementThe managementPrimary surgical resectionHigh-risk diseaseMeaningful clinical responsesGranulocyte-macrophage colony-stimulating factorImmune stimulatory agentsDevelopment of vaccinesMacrophage colony-stimulating factorColony-stimulating factorAdjuvant settingImmunomodulatory therapyAdjuvant optionClinical responseMelanoma vaccineSurgical resectionVaccine therapyClinical outcomes